One year into the global COVID-19 pandemic, much of the global focus is currently going to vaccination rollouts, but treatment options are still limited. However, dexamethasone, an essential medicine which has been around for decades (listed by WHO since 1977) – is one of the few approved treatments for severe and critically ill COVID-19 patients.
New partnership broadens access to oncology treatments across Latin America, Asia, Africa and the Western Pacific
Since the early start of the pandemic we have been supplying PPE and other urgent supplies to countries worldwide, and we have seen the effects of the unforeseen costs that come with it. Budgets need to be reassessed and customers must find a balance between products required and increased transport costs.
IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of ANTI-TUBERCULOSIS MEDICINES AND RELATED PRODUCTS for the treatment of DRUG-RESISTANT FORMS of tuberculosis to eligible manufacturers.
On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis medicine bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.
With corona virus (COVID-19) spreading globally, IDA Foundation is closely monitoring the developments to ensure we are able to respond to any changes. This past week, we were glad to support the Asian Infrastructure Investment Bank (AIIB) by supplying medical goods to be used in the corona virus response in China.
As procurement agent for Stop TB /GDF, we are glad to share this news update as announced by the Stop TB partnership during the 50th Union Conference for Lung Health in Hyderabad, India.
Plus de 3000 professionnels de la santé participeront à la 49e Conférence mondiale sur la santé respiratoire à La Haye: du 24 au 27 octobre 2018.